



Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000
PO Box H100
Australia Square NSW Australia 1215
www.mmjphytotech.com.au
info@mmjphytotech.com.au

ASX RELEASE

25 October 2018

Cannabis Access Clinics collaboration agreement

MMJ Group Holdings Limited (ASX: MMJ) (MMJ) is pleased to note the attached announcement by Bod Australia Limited (ASX: BDA) confirming that they have entered into a collaboration agreement with Cannabis Access Clinics.

MMJ has AUD\$1 million invested in Cannabis Access Clinics for a 17.4% shareholding.

Investor and Media Enquiries

Jason Conroy
Chief Executive Officer

About MMJ

MMJ Group Holdings Limited (ABN 91 601 236 417) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjphytotech.com.au/investors/>

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue **68.5m**
 Market Capitalisation **~\$39m**

BOARD & MANAGEMENT

Mr George Livery
 Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Stephen Thompson
 Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Simon Taylor
 Non-Executive Director

Mr Mickey Perret
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018
 E info@bodaustralia.com.au

Bod secures first medicinal cannabis prescription and enters into research collaboration agreement with Cannabis Access Clinics

- **First prescription of MediCabilis™, Bod's medicinal cannabis product, received from a Cannabis Access Clinics patient – Bod to benefit from additional sales of cannabis oil in the near term**
- **Collaboration also supports observational trial to study the effects of Bod's MediCabilis™ cannabis oil**
- **Agreement provides Bod with access to Cannabis Access Clinics' patient pool and feedback on MediCabilis™' efficacy to treat a range of symptoms**
- **Patients to be recruited from Australia and New Zealand – assists Bod's international expansion initiatives**

Sydney, Australia – 25 October 2018: Developer and distributor of natural, evidence-based cosmetics and health products including medicinal cannabis, Bod Australia Limited ("Bod", the "Company") (ASX: BDA), has received its first prescription and required Special Access Scheme approvals for its MediCabilis™ cannabis oil.

Further, the Company has also entered into a research collaboration agreement with Biologics Research Institute Australia (BRIA), the owners and operators of Cannabis Access Clinics.

Under the research collaboration agreement, Bod and Cannabis Access Clinics will partner to study the effects of Bod's proprietary product, MediCabilis™, (refer image overleaf) on a broad range of patient outcomes. In addition, once Bod completes the Phase I Clinical Trial of its sublingual cannabis wafer (refer ASX announcement: 24 July 2018), it will also be made available to patients in Cannabis Access' network to prescribe when appropriate.

Cannabis Access Clinics have the most extensive network of healthcare clinics assisting doctors and patients to navigate regulatory approvals for prescribing medicinal cannabis products in Australia and New Zealand. (www.cannabisaccessclinics.com.au)

The collaboration provides Bod access to Cannabis Access Clinics extensive patient treatment and monitoring platform across Australia and New Zealand. The trial will provide feedback on MediCabilis™ ability to treat a range of symptoms including anxiety, pain, post chemotherapy nausea and vomiting and epilepsy. The data from the study will assist Bod in refining its Phase II Clinical Trial parameters, which will test specific indications of the product.

Bod is now well positioned to benefit from the ongoing sale of its cannabis oils to patients through approved prescribers.

Bod Australia CEO Jo Patterson said: "This agreement is very beneficial for Bod, as it has not only resulted in the Company receiving its first prescription for MediCabilis™, but also provides us with a large pool of potential patients and prescribers from the Cannabis Access Clinics network that will provide independent and ongoing feedback around our medicinal cannabis product offering.

"Cannabis Access Clinics has the most extensive network of doctors and patients in Australia and New Zealand and are a first mover in navigating the regulatory pathway for prescribing

and monitoring medicinal cannabis therapies. We look forward to working with them and their network of physicians, patients and academics to continue our commitment to better educate the public around the benefits of medicinal cannabis.”

Cannabis Access Clinics Medical Director Dr. Sanjay Nijhawan said: “We place a strong emphasis on ensuring medicinal cannabis is an appropriate treatment for our patients and undertake meticulous monitoring and data collection on an ongoing basis. We are pleased to offer our network of clinics as a research platform to help advance our understanding of how cannabis therapies work for particular patient groups.”

- ENDS -



Image one: Bod’s MediCabilis™ cannabis oil product

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia’s largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

About Cannabis Access Clinics:

Cannabis Access Clinics is the first network of healthcare clinics focused on helping doctors and patients navigate the regulatory pathway for prescribing medicinal cannabis products in Australia and New Zealand.

Cannabis Access works with doctors and patients who suffer from indications for which there is evidence that medicinal cannabis therapies may be beneficial. Cannabis Access Clinics work in accordance with TGA Guidance documents on medicinal cannabis, consulting patients with indications including chronic pain, chemotherapy-induced nausea and vomiting in cancer, multiple sclerosis, PTSD, anxiety, insomnia, epilepsy and HIV aids amongst others.

For more information: cannabisaccessclinics.com.au

For more information please contact:

Jo Patterson
Bod Australia Limited
+61 2 9199 5018

Henry Jordon
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

Belen Gomez
Cannabis Access Clinics
1300 991 477

